



Universiteit
Leiden
The Netherlands

Osteosarcoma : searching for new treatment options

Baranski Madrigal, Z.

Citation

Baranski Madrigal, Z. (2016, May 26). *Osteosarcoma : searching for new treatment options*. Retrieved from <https://hdl.handle.net/1887/39707>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/39707>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/39707> holds various files of this Leiden University dissertation.

Author: Baranski Madrigal, Z.

Title: Osteosarcoma : searching for new treatment options

Issue Date: 2016-05-26

LIST OF PUBLICATIONS

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

Zuzanna Baranski, Tijmen H. Booij, Anne-Marie Cleton-Jansen, Leo Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. *J Pathol* **236**:348-359, 2015

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

Zuzanna Baranski, Yvonne de Jong, Trayana Ilkova, Elisabeth F.P. Peterse, Anne-Marie Cleton-Jansen, Bob van de Water, Pancras C.W. Hogendoorn, Judith V. M. G. Bovée, Erik H.J. Danen. *Oncotarget* **6**:36113-36125, 2015

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation

Zuzanna Baranski, Tijmen H. Booij, Marieke L. Kuijjer, Yvonne de Jong, Anne-Marie Cleton-Jansen, Leo S. Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. *Genes and Cancer*, in press 2015

SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, **Baranski Z**, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH. *Cancer Research* **75**:230-240, 2015

Dasatinib Src inhibitor selectively triggers apoptosis and loss of invasive potential in human osteosarcoma cells

Zuzanna Baranski, Tijmen H. Booij, Anne-Marie Cleton-Jansen, Leo Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. Manuscript in preparation

CURRICULUM VITAE

Zuzanna Baranski Madrigal was born on the 21st of March of 1981 in San Jose, Costa Rica. She studied Pharmacy at the University of Costa Rica from 2000 to 2006. After obtaining her degree, she worked as a pharmacist in Costa Rica from 2006 to 2008. After this period, she travelled to The Netherlands to obtain her Master degree in Biopharmaceutical Sciences at Leiden University. She obtained her degree in 2011.

In 2011 she started as a PhD student at the department of Toxicology at LACDR Institute in Leiden University, under the supervision of Dr. Erik Danen. The project was part of the Translational Drug Discovery and Development grant: Identification and validation of novel kinase drug targets for sarcoma growth & therapy resistance.

She started a postdoctoral fellowship with Dr. Erik Danen the 1st of February, 2016.